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I. Introduction 
A. Autistic Spectrum Disorder 
Autistic spectrum disorder (ASD) is a term referring to the five 
pervasive developmental disorders (PDD) characterized by symptoms in three 
domains: 1) impairments in social interaction, 2) impairments in verbal and 
non-verbal communication, and 3) repetitive behaviors or interests (American 
Psychiatric Association, 2000). These developmental disorders are defined by 
the presence of behavioral symptoms. Diagnostic criteria are defined by the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM IV-TR). The assignment of one of the five subtypes of ASD is 
based upon number and distribution of symptoms among the three main 
domains, as well as age of onset. These five disorders include autistic disorder 
(classic autism), Asperger syndrome, Rett syndrome, child disintegrative 
disorder (CDD) and pervasive developmental disorder not otherwise specified 
(PDD-NOS) (Muhle, et al., 2004). 
The most severe form of ASD is autistic disorder, also known as classic 
autism. This is often the main focus of ASD research.  The diagnostic criteria 
for classic autism as defined by the DSM IV-TR are as follows:  
Patients who qualify as autistic must have at least six of the following 
criteria, with at least two in the first main category at least one in each 
remaining category:  
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I. Qualitative impairment in social interaction manifested by at least two 
of the following:   
1) Impairment in nonverbal behaviors such as facial expressions, gestures and 
eye contact.  
2) Failure to develop peer relationships appropriate for their age.  
3) A lack of seeking to share his/her enjoyments, interests, or achievements 
with others.    
4) Lack of social or emotional reciprocity, including difficulty interpreting or 
understanding the emotions of others.  
II. Qualitative impairments in communication manifested by at least one 
of the following 
5) A delay in, or total lack of, the development of spoken language, without a 
replacement with nonverbal communication like mime or gesture. 
6) Stereotyped and repetitive use of language.  
7) In individuals with adequate speech, marked impairment in the ability to 
initiate or sustain a conversation with others.  
8) Lack of make-believe or social-imitative play.  
III. Restricted repetitive and stereotyped patterns of behavior, interests, 
and activities as manifested by at least one of the following:  
9) Preoccupation with one or more stereotyped and restricted patterns of 
interest that is abnormal either in intensity or focus.  
10) Apparent inflexibility of adherence to specific routines or rituals.  
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11) Stereotyped and repetitive motor mannerisms.  
12) Persistent preoccupation with parts of objects.  
(American Psychiatric Association, 2000)  
Symptoms of autistic disorder are observable in children at a very 
early age. Diagnosis usually occurs between 12 and 30 months of age, when 
lagging developments in language and social interactions become readily 
apparent (US Department of Health and Human Services, 2004). Some 
parents report observable symptoms in their child very early in infancy, with 
some noticing differences just after birth. Others report the change as being 
sudden, with a period of seemingly normal development followed by a 
regression, while still others describe plateau of social and language 
development. 
Asperger syndrome is a higher-functioning autism in which the 
individual develops verbal language appropriate to age. Child disintegrative 
disorder (CDD) is an extremely rare disorder characterized by a period of 
normal development followed by dramatic regression and loss of previously 
acquired skills such as vocabulary and motor skills occurring between two and 
ten years of age. PDD-NOS is a disorder of symptoms similar to autism, but 
does not meet the qualifications of the other four subtypes. Rett syndrome is a 
relatively rare disorder caused by a single point mutation on the X 
chromosome, predominantly affecting females.  It is the only pervasive 
developmental disorders subtype that has a clear and identifiable 
physiological cause (US Department of Health and Human Services, 2004). 
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Rett syndrome and CDD are extremely rare, so for the purposes of this 
paper the term ADS will refer mainly to autistic disorder, Asperger syndrome 
and PDD-NOS. These three disorders differ from one another primarily by the 
number and severity of symptoms. Diagnostic cut-off points between these 
disorders are relatively arbitrary and are defined by qualifications outlined in 
the DSM-IV. 
ASD has become a subject of particular concern to researchers due to 
the dramatic increase in diagnosis in recent years. The most recent studies 
estimate that 1/150 children age 3-10 have an ASD (Center for Disease 
Control, 2007). Within a single decade the number of children diagnosed 
increased nearly ten-fold, from 1/2,500 –1/2,000 in the 1980’s, to 1/333 – 
1/166 in the 1990’s (Szpir, 2006). It is debated that this dramatic increase is 
due primarily to increased awareness of the disorder and changing diagnostic 
standards, however no studies have been conducted to confirm this hypothesis 
(Hertz-Picciotto and Delwiche, 2009).   
B. Causation 
The specific causes of ASD are largely unknown. Epidemiological 
studies have attested genetic inheritance as the predominant cause, however 
no specific genes or gene combinations have been positively identified 
(Muhle, et al. 2004). Monozygotic (MZ) twin studies report an 80 to 90% 
concordance rate of ASD, and a 10% concordance of dizygotic (DZ) twins. 
Phenotypes of concordant twins often vary. A British study found a MZ 
concordance rate of 60% for classic autism, but found a 92% concordance rate 
when expanded to a broader ASD (Baily et al., 1995). This evidence leads us 
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to believe the disorder is caused by an interaction of genetic and non-genetic 
components. Given that the onset of the disorder occurs within the first few 
years of life, contributing environmental factors are likely prenatal. A few 
teratogens have been clearly linked to increased risk for autism. These include 
the chemical agents ethanol, thalidomide and valproic acid, as well as 
infectious agents such as the rubella virus (Arndt, et al. 2005). The effects of 
each of these teratogens are highly dependent on the period of prenatal 
development at which exposure occurred.  
C. Anatomy of an autistic brain 
The neurological deficits that cause the symptoms of ASD are also 
unknown. Multiple brain abnormalities have been found in post-mortem 
analysis of the patients with autism. Brain abnormalities have been noted in 
the brain stem, cerebellum, amygdala, hippocampus, basil ganglia, corpus 
callosum and cerebral cortex (US Department of Health and Human Services, 
2004).  These differences have been found both on the microscopic and 
macroscopic scale, however differences are inconsistent and widely variant 
among autistic patients.  
D. Critical window of environmental exposure 
Thalidomide is an antiemetic that was found to cause severe 
teratogenic effects when taken during the first trimester of pregnancy. Most 
notably, early prenatal exposure led to malformations in limb development 
causing short or even missing limbs (Rodier, et al., 1996). Exposure also 
caused craniofacial malformations including missing ears (both inside and 
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out) and/or deafness as well as increased prevalence of mental retardation and 
autism.  
A Swedish study of thalidomide-exposed patients found that 5 out of 
the 86 thalidomide cases had autism (Rodier, 1996). Among the 86 available 
cases, only 15 had exposure on days 20-24 of gestation, however all 5 autistic 
cases had exposure on these days. Thus, 5/15 or 30% of those who had 
thalidomide exposure on days 20-24 of gestation resulted in autism. This 
finding is highly significant considering the prevalence rate of autism in the 
general population is only 0.6%. Conversely, the rate of autism for all other 
days of thalidomide exposure was 0%.  
Such a substantial increase in autism following exposure to a teratogen 
during this window of development gives insight into the specific brain injury 
that may underlie the neurological deficits associated with autism. At 20-24 
days of gestation, very little of the central nervous system has developed. The 
direct injury caused by the exposure could only occur in areas that were 
present or developing at the time of exposure. This substantially limits the 
area of the direct brain damaged based on developmental stage.  
The critical window of gestation correlates with the period of neural 
tube closure and the development of the first neurons of the brainstem 
(Rodier, 2002). After neural tube closure, the developing brainstem divides 
into the basal and alar plates, giving rise to the cranial motor and sensory 
tracts respectively. These plates further segment into lateral sections called 
rhombomeres, where cells differentiate to form specific cranial nerve nuclei. 
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The critical time of thalidomide exposure suggests that an injury of these early 
developing cranial nerve nuclei may be the initial injury that led to autism.   
Neurological anomalies of the five autistic patients in the study are 
consistent with deficits in specific cranial nerves (Rodier, 1996). Of the five 
patients with autism, three of the cases had Duane syndrome, caused by a 
failure of the abducens (MoVI) nerve that innervates the lateral muscles of the 
eye, four had Moebius Syndrome, caused by failure of the facial nerve 
(MoVII) that innervates facial muscles, and two had abnormal lacrimation, 
caused by a failure of the facial nerve (MoVII) innervation of the lacrimal 
apparatus causing mis-innervation of the neurons that normally supply the 
submandibular structure. Each of the autistic cases also had ear malformations 
and hearing deficits.  
Ear malformations, eye motility problems and Moebius Syndrome 
have been previously associated with autism, showing these malformations 
are not specific to thalidomide-exposed autistic cases (Rodier 1996). All of 
these disorders are linked to brainstem injury. Autopsy cases of non-
thalidomide exposed autistic patients also exhibit deficits in cranial nerves, 
however little research has been conducted to systematically investigate these 
deficits. One non-thalidomide autopsy case discovered a striking 97% 
reduction in the number of neurons in the facial (MoVII) cranial motor 
nucleus (Rodier 1996). This may suggest a malfunction occurred in the 
formation of the rhombomere from which the facial nucleus (MoVII) is 
derived, rhombomere 4. This converging evidence suggests that the initial 
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injury that leads to autism and the cranial nerve deficits may be one in the 
same. 
The thalidomide cases indicate the brain injury leading to autism 
occurs very early in neurological development. Injury must occur in the areas 
that are present or developing at the time of exposure. Early derivatives of the 
brainstem are the only parts of the brain that are present so early in 
development.  The specific injury may cause deficits in mitotic action or a 
disturbance in the formation of specific rhombomeres of the brainstem. 
Progenitor cells that give rise to the rest of the brain are also present, and 
injury in these cells may lead to secondary deficits in later forming brain 
areas. The injury must occur during the period of neural tube closure and 
development of the first neurons. By exposing model animals to chemical 
agents during this window of prenatal development, we may be able to disrupt 
development and create an animal model for autism. 
E. Animal Model 
  Thalidomide does not cause the same teratogenic effect in rodents as 
it does primates. The drug itself is non-teratogenic and damage to the 
developing embryo is caused by a metabolite that is not manufactured in 
rodents (Rodier, 2002). Thus thalidomide is not useful for rodent animal 
studies.  Valproic acid (VPA), an antiepileptic drug and mood stabilizer, 
causes teratogenic effects in rodents similar to those in humans. Prenatal 
exposure is associated with many of the same effects as thalidomide, 
including neurological dysfunctions, limb and craniofacial malformations, and 
an increased incidence of autism (Rodier 2002). VPA-exposed autistic 
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patients also exhibited malformations of the ears indicating damage during the 
same critical window prenatal development.  
Previous rodent studies have found brainstem as well as behavioral 
deficits in VPA-exposed animals (Schneider and Przewlocki, 2005; Rodier et 
al., 1996). Morphological studies of the mouse embryo have demonstrated 
that acute exposure to VPA can cause a failure of neural tube closure and 
disorganization of cells of the neuroepithelium (Rodier, 2002).  This suggests 
that we may be able to reproduce the neurological injuries during the period of 
neural tube closure found in thalidomide cases by exposing rats to VPA 
during this window of development. Examination of brain and behavioral 
deficits may allow us to explore this and develop a rat model for autism.  
The critical developmental window in humans of gestational days 20-
24 (G20-24) correlates with gestational days 9-11 (G9-11) in rats (Sadamatsu, 
et al., 2006). Neural tube closure occurs on approximately G11 and generation 
of the neurons of the cranial nerve motor nuclei begins immediately afterward. 
If exposure to VPA causes effects similar to thalidomide in humans, we would 
predict to find malformations in the cranial nerve nuclei of rats with exposure 
during the window that correlates with days G9-G11. 
 The thalidomide study found that prenatal exposure to 
thalidomide only resulted in autism when exposure occurred between G20-24. 
No autistic cases were found with exposure at any other time during gestation. 
This leads us to believe the teratogenic effects that lead to autism are time-
dependent.  If this is the case, we would predict malformations in the cranial 
nerves only when acute exposure occurs during a specific window of 
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gestation. Exposure on all other days would likely have little effect.  Studies 
of rats with acute prenatal exposure to ethanol have revealed that cranial nerve 
deficits occur within a specific time-dependent window of vulnerability 
(Mooney and Miller, 2007).  Prenatal exposure to ethanol is also associated 
with craniofacial malformations and an increased risk of autism (refs xxx 
Jones and Smith, 1973; Nanson, 1992), This suggests we may see time-
dependent differences in animals with acute prenatal exposure to VPA.  By 
giving animals acute exposure to VPA on different days of gestation spanning 
the expected critical window, we will be able to determine if deficits are 
specific to this period of prenatal development. A window from G9-13, allows 
us to examine the effects of acute exposure from just after gastrulation (G9) to 
the development of the facial cranial nerve neurons (G13) in order to 
determine a critical window of vulnerability.  
Cranial nerves for our study were sampled to determine whether injury 
affected only neurons undergoing their final mitosis during exposure, or 
whether some other factor of selection was involved. To investigate this, we 
studied sensory cranial nerves from multiple rhombomeres to determine the 
presence of specific differences. We combined the present data with 
previously generated data on motor cranial nerve nuclei to compare the effects 
of VPA on both the basal and alar plates. Injury or deletion of an entire 
rhombomere would suggest malformations in nuclei of both plates located on 
the same rhombomere.  
Our study focused on the determining the size and cell density of the 
principal sensory nucleus (PSN) and the oral and interpolar subnuclei of the 
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spinal trigeminal complex (SpVo, and SpVi, respectively). The PSN develops 
on G12-13, from the 3rd rhombomere.  The SpVo develops primarily on G13-
14 from the 5th rhombomere, and the SpVi develops on G14-15 out of the 7th 
rhombomere. By using nuclei on different rhombomeres on both plates that 
develop on different days we may be able to determine how the teratogen 
causes brainstem malformations.  
We hypothesized that acute exposure during the period of neural tube 
closure will lead to deficits in cranial nerve nuclei in a time-and site-
dependent manner.   
II. Materials and Methods: 
A. Animals 
Long Evans rats were mated, and pregnancy was determined by the 
presence of a vaginal plug. The day the plug was found was labeled as the first 
day of gestation (G1). Sodium valproate was dissolved in saline and the  
pH was adjusted to 7.3.  Each treated dam received a single intraperitoneal 
(i.p.) injection of 350mg/kg body weight of sodium valproate in solution on a 
single day of gestation from G9 through G13 inclusive. Control dams were 
given a single intraperitoneal injection of an equivalent volume of saline. The 
day of birth was designated as postnatal day one (P1). On postnatal day 30 
male offspring were taken from each litter and anesthetized with an 
intraperitoneal injection of a 100 mg/kg ketamine and 10 mg/kg xylazine mix.  
The animal was then perfused transcardially with a solution of 4.0% 
paraformaldehyde in 0.10 M phosphate buffer (PB). The brains were 
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removed, post-fixed in a fixative for 4 hours at room temperature, washed in 
PB and stored in fresh PB at 4 °C.  
  Brainstems were isolated and dehydrated through increasing 
concentrations of ethanol, cleared with butanol, then infiltrated with Paraplast 
Plus paraffin. The paraffin embedded tissue was then cut into 5µm sections. 
Half of the samples for each treatment day were cut into sagittal sections 
while the remaining half was cut into horizontal sections. The 5µm sections 
divided the entire brainstem, with one in every 10 sections put on a slide and 
taken for analysis. These sections were de-paraffinized in xylene, rehydrated, 
stained with cresyl violet then dehydrated through increasing concentrations 
of ethanol before being coverslipped.  
B. Anatomic Studies 
Stereological methods were used to estimate the volume and cell density 
of two cranial nerve motor nuclei: the facial (VII) and the trigeminal (V), as 
well as three sensory nuclei: the principal sensory nuclei (PSN) and the oral 
and interpolar subnuclei of the spinal trigeminal nuclear complex (SpVo and 
SpVi respectively).  Estimates of the volume of the cranial nerve nuclei were 
determined by using the Cavalieri estimator (Jenson et al., 1987; Mooney and 
Miller, 2007).  In each section in which the cranial nerve nucleus was visible 
the cross sectional area was measured using the Bioquant Image Analysis 
System (R&M Biometrics, Nashville TN).  The borders of each nucleus were 
determined based on cytoarchitectonic criteria. The neuron cell bodies of the 
each of the two cranial motor nuclei were much larger and more densely 
packed than surrounding cells. The principal sensory was identified based on 
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its disk –shape appearance and its characteristic very small and densely 
packed neurons.  The oral nucleus was identified based on its hourglass 
structure and medium-size neurons organized in striations. The interpolaris 
was identified based on its relatively small medium packed neurons and 
characteristic shape.  
The total volume was determined by summing cross sectional areas 
and multiplying by the section thickness (5µm) times the inverse of the 
section frequency (1/10). This method is illustrated in the formula below:  
VT = Σ As * t/f 
where Σ A
s 
is the sum of the cross sectional areas, t is the section thickness 
(5µm), and f is the frequency of sections in the series (1/10).  
 The cell density of the nuclei was determined using the Smolen 
correction of Abercrombie’s estimator (Abercrombie, 1946; Smolen et al., 
1983; Miller and Muller 1989). The cranial nerve nuclei had been counted by 
a student previously working in the lab. For the cranial nerve motor nuclei, the 
number of motor neurons with visible nucleoli in a 400 x 400 µm area at x 10 
magnification were counted for each section of the brainstem in which the 
nerve nuclei was visible. Only neurons fully within this box, or touching one 
of two adjacent sides of the box were counted. Neurons touching the 
remaining two sides were excluded from counts. The sensory nuclei consist of 
much smaller and more densely packed neurons and thus were estimated 
using same procedure with a 100 x 100 box at a magnification of x 40.  The 
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diameter was measured for each of the counted cells. The neuronal density 
was calculated using the following formula: 
 N
v 
= n * t  / ( t + D
m
 – 2k) 
 
Where Nv is the neuronal cell density, n is the total number of neurons 
counted in the boxes of the nuclei sections, t is the section thickness (5µm), 
D
m 
is the mean maximal diameter of the cell bodies, and k was the diameter of 
the smallest recognizable cap of a cut cell nucleus.   
 Estimates of the volume of the nerve nuclei were multiplied by the 
estimates for cell density in order to approximate the total number of neurons 
within the nucleus.  
C. Statistical Analysis 
The mean ± standard error of the mean was calculated for the volume, 
neuronal cell density, and neuronal number for each nucleus of each treatment 
day. These numbers were subject to a one-way ANOVA, to determine on 
overall effect of treatment. Where significant differences were found, a post-
hoc Tukey test was performed. Significance was set at p = 0.05.  
III. Results 
All five nuclei examined were identifiable in the cresyl violet stained 
sections. There were no gross differences in appearance of nuclei among 
treatment groups.  Analysis of Variance (ANOVA) for the sensory nuclei are 
located in Tables 1-3 in the appendix.  
Principal Sensory Nucleus of the Trigeminal Nerve 
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The volume of the principal sensory nucleus of the trigeminal nerve 
exhibited significant differences among treatment groups (p< .001). A Tukey 
post-hoc analysis found volume to be significantly greater on G13 than in 
control-treated animals (p < .05). No significant differences from controls 
were found in the neuronal cell density or total number of neurons (Figure 1).   
Spinal Trigeminal Nucleus, Oral portion 
The volume of the oral subnuclei of the spinal trigeminal was not 
significantly different compared to controls. The neuronal cell density was 
also did not significantly differ.  The total number of neurons however, was a 
significantly decreased in animals exposed on G13 (Figure 2).  
Spinal Trigeminal Nucleus, Interpolar portions 
 The volume of the interpolar subnuclei of the spinal trigeminal was not 
significantly affected by treatment. There was a significant decrease in 
neuronal cell density with animals exposed on G13. The total number of 
neurons also significantly decreased with exposure on G13 (Figure 3). 
IV. Discussion 
A. Summary of Data  
The total neuronal number of both the oral and interpolar subnuclei of 
the spinal trigeminal significantly decreased following exposure to VPA on 
G13. This time correlates with the peak neuronal generation of the oral 
subnuclei of the spinal trigeminal, and just before peak neuronal generation of 
the interpolar subnuclei of the spinal trigeminal.  Decreased total neuronal 
number with exposure during neuronogenesis of these nuclei suggests VPA 
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exposure may affect cell proliferation. The oral and interpolar subnuclei of the 
spinal trigeminal derive from different rhombomeres, suggesting the 
mechanism that leads to deficits is not selective for a single rhombomere. 
No effects in total neuronal number were seen for the principal sensory 
nucleus (PSN). This nucleus reaches peak neuronal generation at G12-13, 
however, no deficit were seen at G13.  This suggests that the teratogen does 
not merely cause deficits in all neurons undergoing neurogenesis at the time of 
exposure. The teratogen must have an alternate means of selection in order to 
affect the oral and interpolar subnuclei of the trigeminal while sparing the 
principal sensory nucleus. Perhaps the teratogen does not effect rhombomeres 
so far rostal, and only affects the more caudal sections.   
The principal sensory nucleus only exhibited significant differences 
from the control on one occasion, in which the volume of the nuclei was 
significantly greater with exposure on G13. This is the same day in which we 
saw a significant decrease in the total neuronal number in the other two 
sensory nuclei (SpVo and SpVi). Exposure to VPA may have caused an 
inverse effect in the PSN, leading to an increased volume. The total number of 
neurons was not affected so the cause of the increased volume was not due to 
increased neuron proliferation. An increase in the production of fibers or glial 
cells within the nucleus may have accounted for the volume increase.     
To check for differences between effects in the alar and basal plates, 
we compared the sensory data to previously collected motor nuclei data 
(Figures 4 and 5). Neurons of the facial motor nucleus (MoVII) develop on 
G13, out of the 5th rhombomere.  Neurons of the trigeminal motor nucleus 
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(Mo V) form on G12, from the 3rd rhombomere. Analysis of MoV found 
significantly smaller volumes in all treatment groups when compared to the 
controls.  We also found significantly greater cell density in all treatment 
groups when compared to controls. This data combined to yield no significant 
differences in total neuronal number between control and treatment groups.  
Much like the results of MoV, inverse differences in volume and 
neuronal cell density yielded no significant differences in total neuronal 
number the facial (VII) nuclei.   Significantly smaller volumes were found for 
treatment days G9, G11, and G13, and significantly lower neuronal cell 
density was found for the same three treatment days. These results again lead 
to no significant differences in the total neuronal cell number.  
It is difficult to draw conclusions on VPA affect on the two motor 
nuclei. The control data for the motor nuclei had not been conducted so 
control data used for analysis was taken from a study on time-dependent 
effects of ethanol exposure on cranial nerves (Mooney and Miller, 2007). 
While this was control data and thus should have little effect on the analysis, 
differences in inter-rater counting techniques may have affected our results. 
From the data it is difficult to draw specific conclusions about the effect of 
treatments when compared to controls, however it appears the treatment had 
little effect on the total neuronal number on the motor cranial nerves that were 
examined, and no time-dependent differences were revealed.  This suggests 
that the basal plate was largely protected from VPA-induced toxicity. 
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B. Literature Comparison 
A study of time-dependent differences in rat cranial nerves with acute 
exposure to ethanol found a significant decrease in total neuronal number in 
the principal sensory nucleus, the trigeminal motor nucleus (MoV), and the 
facial nucleus (MoVII) after exposure on G12 and G13 (Mooney and Miller, 
2007). No significant differences were found in the SpVo or SpVi. These 
findings do not parallel the effects seen with prenatal VPA, suggesting that 
ethanol and VPA may affect different areas of the brain selectively.  That said, 
exposure to a teratogen on G13 has an effect on both cranial motor and 
sensory nuclei, and thus, is a window of vulnerability for cranial nerve nuclei.. 
This may be due to the window of neuronogenesis, or an alternate factor 
arising during this time of development. 
 
A similar study on the prenatal effects of VPA on cranial nerves found 
no effect in the facial nuclei following acute exposure on rats on days G11.5, 
G12 and G 12.5 (note that G12.5 in this study = G13 in our study; Rodier, 
1996). This is consistent with the data we found, and suggests that acute VPA 
exposure does not affect the facial nucleus. The Rodier study did not give data 
for nuclei volume and neuronal density.  
The same study by Rodier did not parallel our results for MoV. They 
reported a significant decrease in neuronal number of the trigeminal (MoV) 
with exposure on G11.5 and G12, while our study did not find any significant 
changes after treatment on G12 (equivalent to their G11.5).  It is unclear why 
we did not find similar results in the trigeminal (MoV). Difference in results 
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may be due to experimental techniques. More studies need to be conducted in 
order to determine whether the trigeminal neuronal number is affected.  
Our data did not find any effects in neuronal number of the motor 
nuclei, but did find decreased neuronal number in two sensory nuclei. This 
suggests the alar plate may be more susceptible to deficits caused by VPA 
exposure. No differences in the PSN show that not all nuclei of the alar plate 
undergoing neuronogenesis are affected, suggesting other factors of selection 
must be involved.  
The oral and interpolar subnuclei of the spinal trigeminal complex 
exhibited a significant decrease in neuronal number following exposure to 
VPA on G13. This data suggests that deficits caused by VPA exposure may 
target more than one rhombomere as both the oral and interpolar subnuclei are 
affected.  
Convergent data with other VPA studies and ethanol studies suggest 
teratogen exposure may cause greater deficits in the cranial nerves when 
exposed on G13 than on surrounding days. Exposure to VPA in rats on G13 
appears to be a critical window, leading to deficits in the oral and interpolar 
subnuclei of the spinal trigeminal.  
 
C. Future Research 
More motor nuclei must be examined to determine if the basal plate is 
at all affected by VPA exposure. Studies should also retest the trigeminal 
(MoV) in order to determine why we did not see differences in neuronal 
number while the Rodier study did find differences. We should also examine 
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sensory nuclei deriving from other rhombomers, to determine where an affect 
is evident. This will help us understand why effects were seen in the two 
subnuclei of the trigeminal (SpVo and SpVi), but not seen in the PSN. 
 Research should also look into brain deficits in higher-functioning 
parts of the brain in VPA exposed rats, such as the amygdala and the cerebral 
cortex, in order to determine the presence of secondary effects caused by 
acute exposure to VPA during the critical window of exposure (which appears 
to be G13). Studies may then expand to examine behavioral deficits in order 
to further develop VPA exposed rats as an animal model for autism. 
The VPA model for autism has serious potential for aiding in autism 
treatment and research. Discovery of a possible window of vulnerability leads 
to significant insight on the parts of the brain that may be affected, namely the 
brainstem. Research can expand beyond the cranial nerve nuclei to determine 
what parts of the mature brain are damaged by teratogenic exposure during 
neural tube closure and generation of the first neurons. We can also research 
higher functioning parts of the mature brain that may have been secondary 
effects of damage caused in development of the brainstem. While the initial 
damage that leads to autism a may occur in the brainstem, these secondary 
affects may lead to symptoms observed in autism. 
Any animal model of autism is inherently limited due to the diagnostic 
standard, based on communication, social interaction and emotional 
reciprocity which cannot be seen in animal models to the same extent as 
humans. A number of studies have developed to test for autistic traits, 
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particularly with social interaction and repetitive behaviors (Crawley, 2007). 
These tests have yielded promising results for the VPA exposed rat as a model 
for autism.  Behavioral tests have found VPA exposed rats to exhibit autistic 
traits such as increased repetitive behaviors and latency to social behavior 
(Schneider, 2005).  Communication deficits have also been examined by 
testing ultrasonic vocalization patterns (Crawley, 2007). The formation of 
refined behavioral tests may allow us to further explore how this model may 
parallel the symptoms of autism. Further research must be conducted using 
VPA exposure and behavioral tests in tandem to determine connections 
between behavioral and neurological deficits observed. We must combine this 
with more autopsy cases in order to determine the presence of consistent 
neurological deficit in autistic patients.  
Development of a rat model for autism will help researchers 
understand the disorder, as well as provide a mechanism for exploring 
treatments.  Tests have already shown some success in altering behavioral 
deficits in VPA exposed rats through particular therapies and enriched 
environments.  (Schneider, et al., 2006). The development of an animal model 
will be particularly useful in creating and testing neuropharmacological drugs 
to treat autism in the future. 
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VI. Appendix 
 
Table 1 
ANOVA Analyses of Nuclear Volume 
Cranial Nerve         F – statistic          Degrees of                 P value 
Nuclei                                                   freedom              
PSN 9.555 5 <0.001* 
SpVo 5.784 5 0.002* 
SpVi 3.000 5 0.037* 
Mo V 14.455 5 <0.001* 
Mo VII 11.066 5 <0.001* 
 
Table 2 
ANOVA Analyses of Neuronal Cell Density  
Cranial Nerve 
Nuclei 
F - statistic Degrees of 
freedom 
P value 
PSN 5.612 5 0.002* 
SpVo 6.618 5 <0.001* 
SpVi 6.432 5 <0.001* 
Mo V 12.685 5 <0.001* 
Mo VII 11.160 5 <0.001* 
 
Table 3 
ANOVA Analyses of Total Neuronal Number 
Cranial Nerve 
Nuclei 
F - statistic Degrees of 
freedom 
P value 
PSN 1.725 5 0.173 
SpVo 4.762 5 0.006* 
SpVi 6.443 5 0.001* 
Mo V 1.453  5 0.249 
Mo VII 1.999 5 0.125 
* Statistically significant difference 
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Figure 1 Figure 2 Figure 3 
Figure 4 Figure 5 
  
*Statistically significant difference 
from control 
